Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
- Posted on February 17, 2026
- By Forbes
- 2 Views
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer Jennifer Doudna wants to build an entire ecosystem to bring these treatments mainstream.
-in-Munich-85s66qr9.jpeg?trim=0,0,0,0&width=1200&height=800&crop=1200:800)